ACRS = MC $44 M / Cash $115 M/ Phase 3 readout imminent

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
ACRS = MC $44 M / Cash $115 M/ Phase 3 readout imminent

An SI Board Since September 2019

Posts	SubjectMarks	Bans	Symbol
23	1	0	ACRS

Emcee: BioHero	Type: Moderated

Introduction Market Data Compact

BRUTAL Hot Rebound Play which is massive underpriced here trading wayyy below cash ....

Market Cap $43 M / Cash $115 M or untill end 2021 / 2 Marketed Product / 1 Phase 3 trial (common warts) with results expected in Q4 2019 and many other phase 2 programs / because of their strategic change they wants to out-license all their Products which means HUGE upfront payments for the company (more infos below)= CHEAPEST Biotech you can get at this time

Aclaris Therapeutics (ACRS)

Market Cap: $43 M
Cash: $115 M or enough untill end 2021

Price $1.07

Aclaris Therapeutics Announces New Strategic Direction
investor.aclaristx.com

ACRS aquired a attractive drug from Allergan last year paid $65 m upfront alone for this drug which they now looking to outlicense .
globenewswire.com

Pipeline

aclaristx.com

Largest Shareholders:

Deerfield Management Company LP...5 893 416
Franklin Advisers, Inc....3 953 203
BlackRock Fund Advisors ...2 359 223
Broadfin Capital LLC...2 280 260
D. E. Shaw & Co. LP....2 049 462
Sofinnova Ventures, Inc.....1 911 573
Vivo Capital LLC ....1 647 214
Fidelity Management & Research Co...1 562 190
Polar Capital LLP...1 443 920
The Vanguard Group, Inc...1 142 022

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
23	William Blair sees 'significant value disconnect' in Aclaris Therapeutic	BioHero	-	10/11/2019
22	Great News out ...could hit $2 today...up 26% in pre mkt Aclaris Therapeutic	BioHero	-	10/11/2019
21	ACRS..Eskata approval likely next week guys , 10 months review timeline like in	BioHero	-	10/10/2019
20	$2++ coming and going wayyy higher on Partnership news and Phase 3 results	BioHero	-	10/7/2019
19	Price $1.13 ...Market cap $45 Million ...Cash $115Million ...Book Value $3.30 ..	BioHero	-	10/7/2019
18	Major breakout coming .... [graphic]	BioHero	-	10/4/2019
17	What you get for the Market Cap of laughable $42 Million = you get $115 M of Cas	BioHero	-	10/3/2019
16	Book Value $3.30 / Cash per Share $2.79 / 2+ years of Cash / 2 Approved Drugs /	BioHero	-	9/30/2019
15	New presentation investor.aclaristx.com	BioHero	-	9/27/2019
14	With One Late-Stage Study Out Of The Way, Aclaris Moves One Inch Closer To Comme	BioHero	-	9/26/2019
13	next breakout to $2+coming	BioHero	-	9/25/2019
12	Eskata approval in Canada expected within 3 Weeks will trigger milestone payment	BioHero	-	9/25/2019
11	With $115 Million Cash or untill late 2021 and more Cash + Royalties from partne	BioHero	-	9/24/2019
10	still a mega buying opportunity here trading massive below cash	BioHero	-	9/23/2019
9	if your a shareholder please put a high gtc sell order in $5 or higher .thank yo	BioHero	-	9/20/2019
8	great buying opp again here ,, more news coming shortly like partner deals and s	BioHero	-	9/19/2019
7	Up 100% and still trading below cash ($2.80 Cash per share )	BioHero	-	9/17/2019
6	BOOOOOOOOOOOOOOOOOOOOOOOM and still trading below cash which alone is $2.80 per	BioHero	-	9/16/2019
5	POSITIVEE PHASE 3 RESULTS YIPPIIIIIIIIIIIIIII Aclaris Therapeutics’ A-101 45% T	BioHero	-	9/16/2019
4	New Major breakout to $2+ could starty anytime now wh [graphic]	BioHero	-	9/16/2019
3	Morgan Stanley reports 5% passive stake in Aclaris Therapeutics...08/29,2019 the	BioHero	-	9/13/2019
2	the cheapest biotech you can get trading massive under cash who has 2 approved d	BioHero	-	9/13/2019
1	great rebound stock which could triple easily [graphic]	BioHero	-	9/12/2019

Go to reply# or date (mm/dd/yy):